Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine
DOI 10.1038/74704

Cited by (1,006)

Items 101–200 of 1,006

  1. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
    Gennari, Roberto, Menard, Sylvie, Fagnoni, Francesco, Ponchio, Luisa, Scelsi, Mario, Tagliabue, Elda, Castiglioni, Fabio, Villani, Laura, Magalotti, Cesare, Gibelli, Nadia et al. · 2004 · Clinical Cancer Research
  2. Mechanisms of killing by anti-CD20 monoclonal antibodies
    Martin J. Glennie, Ruth R. French, Mark Steven Cragg, Ronald P. Taylor · 2007 · Molecular Immunology
  3. Type I and type II Fc receptors regulate innate and adaptive immunity
    Andrew Pincetic, Stylianos Bournazos, David J. DiLillo, Jad Maamary, Taia T. Wang, Rony Dahan, Benjamin M. Fiebiger, Jeffrey V. Ravetch · 2014 · Nature Immunology
  4. Human natural killer cell development and biology
    Sherif Shafik Farag, Michael A. Caligiuri · 2005 · Blood Reviews
  5. Resistance to Trastuzumab in Breast Cancer
    Paula Raffin Pohlmann, Ingrid A. Mayer, Ray L. Mernaugh · 2009 · Clinical Cancer Research
  6. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
    Stagg, John, Loi, Sherene, Divisekera, Upulie, Ngiow, Shin Foong, Duret, Helene, Yagita, Hideo, Teng, Michele W., Smyth, Mark J. · 2011 · Proceedings of the National Academy of Sciences
  7. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
    Eichhorn, Pieter J.A., Gili, Magüi, Scaltriti, Maurizio, Serra, Violeta, Guzman, Marta, Nijkamp, Wouter, Beijersbergen, Roderick L., Valero, Vanesa, Seoane, Joan, Bernards, René et al. · 2008 · Cancer Research
  8. Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin
    Cary D. Austin, Ann M. G. L. De Mazière, Paul I. Pisacane, Suzanne van Dijk, Charles W. Eigenbrot, Mark X. Sliwkowski, Judith Klumperman, Richard H. Scheller · 2004 · Molecular Biology of the Cell
  9. Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
    Ritter, Christoph A., Perez-Torres, Marianela, Rinehart, Cammie, Guix, Marta, Dugger, Teresa, Engelman, Jeffrey A., Arteaga, Carlos L. · 2007 · Clinical Cancer Research
  10. Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
    Neil L. Spector, Kimberly Blackwell · 2009 · Journal of Clinical Oncology
  11. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
    Devika Gajria, Sarat Chandarlapaty · 2011 · Expert Review of Anticancer Therapy
  12. What does it take to make a natural killer?
    Francesco Colucci, Michael A. Caligiuri, James P. Di Santo · 2003 · Nature reviews. Immunology
  13. Breast Cancer Treatments: Updates and New Challenges
    Anna Burguin, Caroline Diorio, Francine Durocher · 2021 · Journal of Personalized Medicine
  14. Immune Regulation of Cancer
    Mary Lenora Disis · 2010 · Journal of Clinical Oncology
  15. FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
    Wu Zhang, Michael A. Gordon, Anne Maria Schultheis, Dongyun Yang, Fumio Nagashima, Mizutomo Azuma, Heung-Moon Chang, E. Borucka, Georg Lurje, Andy E. Sherrod et al. · 2007 · Journal of Clinical Oncology
  16. Elimination mechanisms of therapeutic monoclonal antibodies
    Mohammad A. Tabrizi, Chih-Ming L. Tseng, Lorin K. Roskos · 2006 · Drug Discovery Today
  17. From bench to bedside: the history and progress of CAR T cell therapy
    Aroshi Mitra, Amrita Barua, Luping Huang, Siddhartha Ganguly, Qin Fu Feng, Bin He · 2023 · Frontiers in Immunology
  18. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
    Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Herve R. Bonnefoi, Guy Jérusalem et al. · 2019 · The Lancet Oncology
  19. Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
    Robert S. Kerbel · 2006 · Science
  20. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
    Margaret E. Ackerman, Brian Moldt, Richard T. Wyatt, Anne‐Sophie Dugast, Elizabeth G. McAndrew, Stephen Tsoukas, Stéphanie Jost, Christoph T. Berger, Gaia Sciaranghella, Qingquan Liu et al. · 2010 · Journal of Immunological Methods
  21. Herceptin: mechanisms of action and resistance
    Rita Nahta, Francisco J. Esteva · 2005 · Cancer Letters
  22. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
    Yannick Bulliard, Rose Jolicoeur, Maurice Windman, Sarah M. Rue, Seth A. Ettenberg, Deborah A. Knee, Nicholas S. Wilson, Glenn Dranoff, Jennifer L. Brogdon · 2013 · The Journal of Experimental Medicine
  23. EGFR Signaling and Drug Discovery
    Georg Lurje, Heinz‐Josef Lenz · 2009 · Oncology
  24. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
    Maurizio Scaltriti, Chandra Shekhar Verma, Marta Guzmán, José Jimenez, Josep-Lluís Parra, Kim Pedersen, Derek John Smith, Stefania Landolfi, Santiago Ramón y Cajal, Joaquı́n Arribas et al. · 2008 · Oncogene
  25. Rituximab-Dependent Cytotoxicity by Natural Killer Cells
    Dall’Ozzo, Sébastien, Tartas, Sophie, Paintaud, Gilles, Cartron, Guillaume, Colombat, Philippe, Bardos, Pierre, Watier, Hervé, Thibault, Gilles · 2004 · Cancer Research
  26. HER2 therapy: Molecular mechanisms of trastuzumab resistance
    Rita Nahta, Francisco J. Esteva · 2006 · Breast Cancer Research
  27. Biologic and therapeutic role of HER2 in cancer
    Sylvie Ménard, Serenella Maria Pupa, Manuela Campiglio, Elda Tagliabue · 2003 · Oncogene
  28. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    Jennifer H. Anolik, Debbie Campbell, Raymond E. Felgar, Faith M Young, Iñaki Sanz, Joseph D. Rosenblatt, Richard John Looney · 2003 · Arthritis & Rheumatism
  29. Optimization of humanized IgGs in glycoengineered Pichia pastoris
    Huijuan Li, Natarajan Sethuraman, Terrance A. Stadheim, Dongxing Zha, Bianka Prinz, Nicole L Ballew, Piotr Bobrowicz, Byung‐Kwon Choi, W. James Cook, Michael C. Cukan et al. · 2006 · Nature Biotechnology
  30. Receptor-targeted nanocarriers for therapeutic delivery to cancer
    Bo Yu, Heng-Chiat Tai, Weiming Xue, L. James Lee, Robert J. Lee · 2010 · Molecular Membrane Biology
  31. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
    Josée Golay, Manuela Lazzari, Valeria Facchinetti, Sergio Bernasconi, Gianmaria Borleri, Tiziano Barbui, Alessandro Rambaldi, Martino Introna · 2001 · Blood
  32. Fc‐Receptors as Regulators of Immunity
    Falk Nimmerjahn, Jeffrey V. Ravetch · 2007 · Advances in immunology
  33. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
    Frederick Arce Vargas, Andrew J.S. Furness, Isabelle Solomon, Kroopa Joshi, Leila Mekkaoui, Marta H. Lesko, Enrique Miranda, Rony Dahan, Andrew Georgiou, Anna Śledzińska et al. · 2017 · Immunity
  34. The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
    Ronit Vogt Sionov, Zvi Gregorio Fridlender, Zvi Granot · 2014 · Cancer Microenvironment
  35. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
    James D Mellor, Michael Paul Brown, Helen Ruth Irving, John Raymond Zalcberg, Alexander Dobrovic · 2013 · Journal of Hematology & Oncology
  36. VISTA is an acidic pH-selective ligand for PSGL-1
    Robert J. Johnston, Linhui Julie Su, Jason Pinckney, David Critton, Eric Boyer, Arathi M. Krishnakumar, Martin J. Corbett, Andrew L. Rankin, Rose A. DiBella, Lynne Campbell et al. · 2019 · Nature
  37. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
    Rony Dahan, Emanuela I. Sega, John Engelhardt, Mark Selby, Alan J. Korman, Jeffrey V. Ravetch · 2015 · Cancer Cell
  38. Functional roles of N ‐glycans in cell signaling and cell adhesion in cancer
    Yan‐Yang Zhao, Motoko Takahashi, Jianguo Gu, Eiji Miyoshi, Akio Matsumoto, Shinobu Kitazume, Naoyuki Taniguchi · 2008 · Cancer Science
  39. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
    Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John Paul Crown, Jonathan A. Polikoff, Jean-François Boileau, Louise Provencher et al. · 2019 · Journal of Clinical Oncology
  40. Engineered antibodies
    Peter J. Hudson, Christelle Souriau · 2003 · Nature Medicine
  41. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
    Mark Steven Cragg, Suzanne M. Morgan, H.T. Claude Chan, B. Paul Morgan, Alexander V. Filatov, Peter Johnson, Ruth R. French, Martin J. Glennie · 2003 · Blood
  42. Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
    David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Y. Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman et al. · 2005 · Journal of Clinical Oncology
  43. The role of exosomes in cancer metastasis
    Teresa Bernadette Steinbichler, József Dudás, Herbert Riechelmann, Ira Skvortsova · 2017 · Seminars in Cancer Biology
  44. Antibody-targeted radiation cancer therapy
    Milenic, Diane E., Brady, Erik D., Brechbiel, Martin W. · 2004 · Nature Reviews Drug Discovery
  45. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
    Adam M. Boruchov · 2005 · Journal of Clinical Investigation
  46. Rituximab: Mechanism of action and resistance
    David G. Maloney, Barbara Smith, Andrea L. Rose · 2002 · Seminars in Oncology
  47. A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
    Erika Kovács, Julie Anne Zorn, Yongjian Huang, Tiago F. Barros, John Kuriyan · 2015 · Annual Review of Biochemistry
  48. Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
    Timothy M. Pierpont, Candice Limper, Kristy L. Richards · 2018 · Frontiers in Oncology
  49. Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
    Brent Neil Rexer, Carlos L. Arteaga · 2012 · Critical Reviews™ in Oncogenesis
  50. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
    Olivier Manches, Gabrielle Lui, Laurence Chaperot, Rémy Gressin, Jean‐Paul Molens, Marie‐Christine Jacob, Jean‐Jacques Sotto, Dominique Leroux, Jean‐Claude Bensa, Joël Plumas · 2003 · Blood
  51. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression
    Heléne Piccard, Ruth J. Muschel, Ghislain Opdenakker · 2011 · Critical Reviews in Oncology/Hematology
  52. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
    Martine J Piccart, Eileen McCormick Holmes, Jose M Baselga, Evandro de Azambuja, Amylou Constance Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Alison A. Armour, Kathleen I. Pritchard et al. · 2015 · Journal of Clinical Oncology
  53. B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
    Flavius Martin, Andrew C. Chan · 2006 · Annual Review of Immunology
  54. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
    John C. Byrd, Shinichi Kitada, Ian W. Flinn, Jennifer L. Aron, Michael Pearson, David M Lucas, John C. Reed · 2002 · Blood
  55. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20
    Domenico Ettore Sansonno, Vallì De Re, Gianfranco Lauletta, Felicia Anna Tucci, Mauro Boiocchi, Franco Dammacco · 2003 · Blood
  56. Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
    Gregg J. Silverman, Stuart Weisman · 2003 · Arthritis & Rheumatism
  57. The Biology of CD20 and Its Potential as a Target for mAb Therapy
    Mark Steven Cragg, Claire A. Walshe, Andrey Ivanov, Martin J. Glennie · 2004 · KARGER eBooks
  58. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    John F. DiJoseph, Douglas C. Armellino, Erwin R. Boghaert, Kiran M. Khandke, Maureen M. Dougher, Latha Sridharan, Arthur Kunz, Philip R. Hamann, Boris Gorovits, Chandrasekhar Udata et al. · 2003 · Blood
  59. Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia
    Adam D. Kennedy, Paul V. Beum, Michael D. Solga, David J. DiLillo, Margaret A. Lindorfer, Charles E. Hess, John J. Densmore, Michael E. Williams, Ronald P. Taylor · 2004 · The Journal of Immunology
  60. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
    Mark Steven Cragg, Martin J. Glennie · 2003 · Blood
  61. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
    Schäfer, Alexandra, Muecksch, Frauke, Lorenzi, Julio C.C., Leist, Sarah R., Cipolla, Melissa, Bournazos, Stylianos, Schmidt, Fabian, Maison, Rachel M., Gazumyan, Anna, Martinez, David R. et al. · 2021 · Journal of Experimental Medicine
  62. The Carbohydrate at FcγRIIIa Asn-162
    Claudia Ferrara, Fiona Stuart, Peter Sondermann, Peter Brünker, Pablo Umaña · 2005 · Journal of Biological Chemistry
  63. Tumor-Associated Macrophages in Breast Cancer
    Russell Leek, Adrian Llewellyn Harris · 2002 · Journal of Mammary Gland Biology and Neoplasia
  64. “Of mice and men”
    Kelland, L.R. · 2004 · European Journal of Cancer
  65. Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody
    Torsten Dreier, Grit Lorenczewski, Christian Brandl, Patrick Hoffmann, Uwe Syring, Frank Hanakam, Peter Kufer, Gert Riethmüller, Ralf Christian Bargou, Patrick A. Baeuerle · 2002 · International Journal of Cancer
  66. Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
    Kavita M. Dhodapkar, Joseph Krasovsky, Barbara Williamson, Madhav V. Dhodapkar · 2002 · The Journal of Experimental Medicine
  67. On guard—activating NK cell receptors
    Lewis L. Lanier · 2001 · Nature Immunology
  68. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 <sup>+</sup> breast cancer patients
    Scaltriti, Maurizio, Eichhorn, Pieter J., Cortés, Javier, Prudkin, Ludmila, Aura, Claudia, Jiménez, José, Chandarlapaty, Sarat, Serra, Violeta, Prat, Aleix, Ibrahim, Yasir H. et al. · 2011 · Proceedings of the National Academy of Sciences
  69. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
    Alon D. Levin, Manon E. Wildenberg, Gijs R. VAN DEN BRINK · 2016 · Journal of Crohn s and Colitis
  70. Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa
    Akira Okazaki, Emi Shoji-Hosaka, Kazuyasu Nakamura, Masako Wakitani, Kazuhisa Uchida, Shingo Kakita, Kouhei Tsumoto, Izumi Kumagai, Kenya Shitara · 2004 · Journal of Molecular Biology
  71. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis
    Edward Clark Keystone, Roy Fleischmann, Paul Emery, Daniel E. Fürst, Ronald van Vollenhoven, Joan M. Bathon, Maxime Dougados, Andrew R. Baldassare, Gianfranco Ferraccioli, Andrew Chubick et al. · 2007 · Arthritis & Rheumatism
  72. Trastuzumab: triumphs and tribulations
    Rita Nahta, Francisco J. Esteva · 2007 · Oncogene
  73. Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
    Fubin Li, Jeffrey V. Ravetch · 2011 · Science
  74. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
    Stephen A. Beers, Ruth R. French, H.T. Claude Chan, Sean H. Lim, Timothy C. Jarrett, Regina Mora Vidal, Sahan S. Wijayaweera, Sandra V. Dixon, Hyungjin Kim, Kerry L. Cox et al. · 2010 · Blood
  75. Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma
    Kai Fu, Dennis D. Weisenburger, William W.L. Choi, Kyle Perry, Lynette M. Smith, Xinlan Shi, Christine P. Hans, Timothy C. Greiner, Philip Jay Bierman, R. Gregory Bociek et al. · 2008 · Journal of Clinical Oncology
  76. β1 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and <i>In vivo</i>
    Park, Catherine C., Zhang, Hui, Pallavicini, Maria, Gray, Joe W., Baehner, Frederick, Park, Chong J., Bissell, Mina J. · 2006 · Cancer Research
  77. Monoclonal TCR-redirected tumor cell killing
    Nathaniel Liddy, Giovanna Bossi, Katherine J. Adams, Anna Lissina, Tara Mahon, Namir J. Hassan, Jessie Gavarret, Frayne Bianchi, Nicholas J. Pumphrey, Kristin Ladell et al. · 2012 · Nature Medicine
  78. Complement activation plays a key role in the side‐effects of rituximab treatment
    Lizet E. van der Kolk, A.J. Grillo-López, Johanna W. Baars, C. Erik Hack, Marinus H. J. van Oers · 2001 · British Journal of Haematology
  79. Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma
    Rinpei Niwa, Emi Shoji-Hosaka, Mikiko Sakurada, Toyohide Shinkawa, Kazuhisa Uchida, Kazuyasu Nakamura, Kouji Matsushima, Ryuzo Ueda, Nobuo Hanai, Kenya Shitara · 2004 · Cancer Research
  80. Iminosugars past, present and future: Medicines for tomorrow
    Horne, Graeme, Wilson, Francis X., Tinsley, Jon, Williams, David H., Storer, Richard · 2011 · Drug Discovery Today
  81. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases
    Hadassa Waterman, Yosef Yarden · 2001 · FEBS Letters
  82. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
    John O. Richards, Sher Karki, Greg A. Lazar, Hsing Chen, Wei Dang, John R. Desjarlais · 2008 · Molecular Cancer Therapeutics
  83. Natural and therapy-induced immunosurveillance in breast cancer
    Guido Kroemer, Laura Senovilla, Lorenzo Galluzzi, Fabrice André, Laurence Zitvogel · 2015 · Nature Medicine
  84. Mouse model recapitulating human Fcγ receptor structural and functional diversity
    Patrick T Smith, David J. DiLillo, Stylianos Bournazos, Fubin Li, Jeffrey V. Ravetch · 2012 · Proceedings of the National Academy of Sciences
  85. Monoclonal antibodies for cancer immunotherapy
    Louis M. Weiner, Madhav V. Dhodapkar, Soldano Ferrone · 2009 · The Lancet
  86. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages
    Shicheng Su, Jinghua Zhao, Yue Xing, Xiaoqian Zhang, Jiang Liu, Qian Ouyang, Jianing Chen, Fengxi Su, Qiang Liu, Erwei Song · 2018 · Cell
  87. NK Cells and Cancer
    Loris Zamai, Cristina Ponti, Prisco Mirandola, Giuliana Gobbi, Stefano Papa, Laura Galeotti, Lucio Cocco, Marco Vitale · 2007 · The Journal of Immunology
  88. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
    Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J. Cheadle, Sandeep Potluri, Sean H. Lim, Kazuyuki Shimada, H.T. Claude Chan, Alison Tutt, Stephen A. Beers et al. · 2011 · Blood
  89. Current Developments in Cancer Vaccines and Cellular Immunotherapy
    Antoni Ribas, Lisa Helene Butterfield, John A. Glaspy, James S. Economou · 2003 · Journal of Clinical Oncology
  90. Mechanisms of immune evasion in breast cancer
    Joshua P. Bates, Roshanak Derakhshandeh, Laundette P. Jones, Tonya J. Webb · 2018 · BMC Cancer
  91. FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy
    Nina M. van Sorge, W-L van der Pol, Jan G. J. van de Winkel · 2003 · Tissue Antigens
  92. Signal transduction and oncogenesis by ErbB/HER receptors
    Marmor, Mina D, Skaria, Kochupurakkal Bose, Yarden, Yosef · 2004 · International Journal of Radiation Oncology*Biology*Physics
  93. Clinical trials of antibody therapy
    Martin J. Glennie, Peter Johnson · 2000 · Immunology Today
  94. Towards personalized treatment for early stage HER2-positive breast cancer
    Kristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Carmine De Angelis, Charles Kent Osborne, Mothaffar Fahed Rimawi, Rachel Schiff · 2019 · Nature Reviews Clinical Oncology
  95. Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic Antibodies
    R. Bhat, C. Watzl · 2007 · PLoS ONE
  96. Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors
    Jeffrey B. Stavenhagen, Sergey N. Gorlatov, Nadine Tuaillon, Christopher T. Rankin, Hua Li, Stephen Burke, Ling Huang, Syd Johnson, Ezio Bonvini, Scott Koenig · 2007 · Cancer Research
  97. The immune system and response to HER2-targeted treatment in breast cancer
    Giampaolo Bianchini, Luca Gianni · 2014 · The Lancet Oncology
  98. PTEN, PIK3CA, p-AKT, and p-p70S6K Status
    Esteva, Francisco J., Guo, Hua, Zhang, Siyuan, Santa-Maria, Cesar, Stone, Steven, Lanchbury, Jerry S., Sahin, Aysegul A., Hortobagyi, Gabriel N., Yu, Dihua · 2010 · The American Journal of Pathology
  99. Antibody-Based Immunotherapy of Cancer
    Louis M. Weiner, Joseph Christopher Murray, Casey W. Shuptrine · 2012 · Cell
  100. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
    Yannick Bulliard, Rose Jolicoeur, Jimin Zhang, Glenn Dranoff, Nicholas S. Wilson, Jennifer L. Brogdon · 2014 · Immunology and Cell Biology